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Objectives: Genital HPV infection in men causes benign and cancerous lesions, the incidence of which
differs by age. The goal of this work was to comprehensively evaluate incidence and clearance of indi-
vidual HPV genotypes among men by age group.
Methods: HIV-negative men ages 18–70 with no history of anogenital cancer were recruited for the HPV
Infection in Men (HIM) Study. Participants completed clinical exams and questionnaires every six months
for up to 4 years. Genital specimens underwent HPV genotyping, with associations between age and
HPV assessed using Cox analyses.
Results: 4085 men were followed for a median of 48.6 months (range: 0.3–94.0). Signiﬁcantly lower HPV
incidence rates were observed among the oldest age group (55–70 years) for grouped high-risk (inci-
dence rate ratio [IRR]¼0.71), HPV16 (IRR¼0.54), grouped low-risk (IRR¼0.74), and HPV6 (IRR¼0.57)
infections compared to men ages 18–24. However, incidence of the grouped 9-valent HPV vaccine types
remained constant across the lifespan. Likelihood of HPV6 and HPV16 clearance remained constant until
age 54, then increased signiﬁcantly for men ages 55–70 (adjusted hazard ratio [AHR]¼1.92 and 1.65,
respectively).
Conclusions: Men remain susceptible to HPV infections throughout their lifespan, highlighting the need
for prevention efforts with long-lasting duration.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Several cancers of the anogenital tract in men are caused by
human papillomavirus (HPV) types 16 and 18, including approxi-
mately 50% of penile cancers [1,2]. The difference in age patterning of
different HPV-related diseases suggests that genital HPV natural
history in men varies by age and HPV type. Penile cancer rates vary
greatly by ethnicity and country, with Brazil having among the
highest penile cancer rates in the world (8/100,000) [3]. Although
current penile cancer rates are relatively low in Denmark and The
Netherlands, both countries have reported trends of rising incidence,
as have other European countries [4,5]. While low rates of penile
cancer are observed in the U.S. (1/100,000), incidence isB.V. This is an open access article u
h in Cancer, H. Lee Mofﬁtt
Drive, Tampa, FL 33617, USA.
iuliano).approximately twofold higher among Hispanics compared to non-
Hispanics [6,7]. Unlike cervical cancer, which occurs at a median age
of 45 years, diagnosis of penile cancer occurs at older ages, with a
median age of Z60 years. In contrast to penile cancer, condyloma
(genital warts), primarily caused by HPV types 6 and 11, occur at
younger ages, with peak incidence in early adulthood (late twenties)
among men [8].
In Latin American studies, cervical HPV prevalence and inci-
dence appear to follow a bimodal age pattern [9–11]. In contrast to
these ﬁndings in women, no overall association has been found
between age and grouped HPV infection incidence and prevalence
among men [12,13]. However, studies to date have not been large
enough to examine the age patterning of HPV infection incidence
and duration by HPV genotype. We hypothesized that cancer-
causing HPV types follow a different pattern with age in men than
do HPV types that cause condyloma, and that this pattern is dif-
ferent than what has been reported among women.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Study design and population
A prospective analysis was conducted within the HPV Infection
in Men (HIM) Study, an ongoing natural history study of HPV
infection among 4085 healthy men in the U.S. (Tampa, Florida),
Brazil (São Paulo), and Mexico (Cuernavaca). HIM Study partici-
pants 18–70 years of age were recruited between 2005 and 2009.
Men were eligible to participate if they had no prior diagnosis of
anogenital cancer, genital warts, or HIV infection at their baseline
visit. Participants were enrolled into the prospective component ofTable 1
Distribution of baseline demographic and behavioral characteristics by age group.
Characteristics Overall (N¼4085) Age group
18–24 (N¼1231) 25–
Country of residence, N (%)
US 1326 (32.5) 734 (59.6) 20
Brazil 1410 (34.5) 261 (21.2) 50
Mexico 1349 (33.0) 236 (19.2) 52
Race, N (%)
White 1818 (44.5) 668 (54.3) 46
Black 636 (15.6) 152 (12.3) 21
Asian/paciﬁc islander 112 (2.7) 81 (6.6) 1
Other/mixed race 1334 (32.7) 248 (20.1) 50
Refused 185 (4.5) 82 (6.7) 5
Education (years), N (%)
o12 905 (22.2) 142 (11.5) 32
12 1086 (26.6) 340 (27.6) 34
13–15 1035 (25.3) 565 (45.9) 17
16 785 (19.2) 161 (13.1) 30
Z17 249 (6.1) 16 (1.3) 8
Refused 25 (0.6) 7 (0.6)
Marital status, N (%)
Single 1833 (44.9) 1066 (86.6) 50
Married 1391 (34.1) 73 (5.9) 43
Cohabiting 484 (11.8) 80 (6.5) 21
Divorced/separated/widowed 355 (8.7) 6 (0.5) 8
Refused 22 (0.5) 6 (0.5)
Current smoker, N (%)
No 3105 (76.0) 978 (79.4) 88
Yes 961 (23.5) 247 (20.1) 35
Refused 19 (0.5) 6 (0.5)
Circumcision, N (%)
No 2570 (62.9) 582 (47.3) 92
Yes 1515 (37.1) 649 (52.7) 31
HPV status at baseline
Positive 2135 (52.3) 544 (44.2) 72
Negative 1950 (47.7) 687 (55.8) 52
Lifetime number of female sex partners, N (%)
0–1 719 (17.6) 339 (27.5) 17
2–9 1621 (39.7) 588 (47.8) 51
10–49 1273 (31.2) 240 (19.5) 41
Z50 228 (5.6) 21 (1.7) 5
Refused 244 (6.0) 43 (3.5) 8
Number of recent female sex partners (within past six months), N (%)
0 1229 (30.1) 347 (28.2) 34
1 1654 (40.5) 514 (41.8) 49
2 525 (12.9) 163 (13.2) 17
Z3 528 (12.9) 183 (14.9) 17
Refused 149 (3.6) 24 (1.9) 5
Lifetime number of male anal sex partners, N (%)
0–1 3619 (88.6) 1124 (91.3) 108
2–9 232 (5.7) 57 (4.6) 6
Z10 162 (4.0) 39 (3.2) 6
Refused 72 (1.8) 11 (0.9) 2
Number of recent male anal sex partners (within past months), N (%)
0 3832 (93.8) 1151 (93.5) 114
Z1 244 (6.0) 78 (6.3) 9
Refused 9 (0.2) 2 (0.2)
P values were derived using Monte Carlo estimation of the exact Pearson chi-squared test
sex partners. Data reﬂect responses collected at baseline.the study upon completion of their ﬁrst follow-up visit (two weeks
post-baseline). Additional follow-up visits occurred every six
months thereafter for up to 4 years. Details of the HIM Study
have been previously published [13]. Less than 1% of HIM Study
participants reported receiving 41 dose of an HPV vaccine post-
licensure (after 2009). Participants provided written informed
consent, and procedures were approved by the following human
subjects committees: University of South Florida, Ludwig Institute
for Cancer Research, Centro de Referência e Treinamento em
Doencas Sexualmente Transmissiveis e AIDS (CRT-DST/AIDS), and
Instituto Nacional de Salud Pública de México.34 (N¼1245) 35–44 (N¼1082) 45–54 (N¼351) 55–70 (N¼176)
9 (16.8) 210 (19.4) 99 (28.2) 74 (42.0)
9 (40.9) 462 (42.7) 123 (35.0) 55 (31.3)
7 (42.3) 410 (37.9) 129 (36.8) 47 (26.7)
0 (36.9) 445 (41.1) 144 (41.0) 101 (57.4)
0 (16.9) 180 (16.6) 69 (19.7) 25 (14.2)
3 (1.0) 16 (1.5) 1 (0.3) 1 (0.6)
6 (40.6) 403 (37.2) 129 (36.8) 48 (27.3)
6 (4.5) 38 (3.5) 8 (2.3) 1 (0.6)
4 (26.0) 295 (27.3) 95 (27.1) 49 (27.8)
7 (27.9) 301 (27.8) 79 (22.5) 19 (10.8)
8 (14.3) 176 (16.3) 71 (20.2) 45 (25.6)
5 (24.5) 212 (19.6) 69 (19.7) 38 (21.6)
2 (6.6) 93 (8.6) 35 (10.0) 23 (13.1)
9 (0.7) 5 (0.5) 2 (0.6) 2 (1.1)
0 (40.2) 205 (18.9) 48 (13.7) 14 (8.0)
7 (35.1) 580 (53.6) 189 (53.8) 112 (63.6)
2 (17.0) 148 (13.7) 39 (11.1) 5 (2.8)
7 (7.0) 144 (13.3) 74 (21.1) 44 (25.0)
9 (0.7) 5 (0.5) 1 (0.3) 1 (0.6)
8 (71.3) 825 (76.2) 264 (75.2) 150 (85.2)
0 (28.1) 253 (23.4) 86 (24.5) 25 (14.2)
7 (0.6) 4 (0.4) 1 (0.3) 1 (0.6)
9 (74.6) 746 (68.9) 220 (62.7) 93 (52.8)
6 (25.4) 336 (31.1) 131 (37.3) 83 (47.2)
5 (58.2) 588 (54.3) 185 (52.7) 93 (52.8)
0 (41.8) 494 (45.7) 166 (47.3) 83 (47.2)
1 (13.7) 153 (14.1) 40 (11.4) 16 (9.1)
7 (41.5) 365 (33.7) 103 (29.3) 48 (27.3)
4 (33.3) 400 (37.0) 149 (42.5) 70 (39.8)
9 (4.7) 92 (8.5) 29 (8.3) 27 (15.3)
4 (6.7) 72 (6.7) 30 (8.5) 15 (8.5)
9 (28.0) 347 (32.1) 115 (32.8) 71 (40.3)
6 (39.8) 420 (38.8) 154 (43.9) 70 (39.8)
1 (13.7) 138 (12.8) 39 (11.1) 14 (8.0)
3 (13.9) 135 (12.5) 23 (6.6) 14 (8.0)
6 (4.5) 42 (3.9) 20 (5.7) 7 (4.0)
8 (87.4) 940 (86.9) 313 (89.2) 154 (87.5)
7 (5.4) 77 (7.1) 17 (4.8) 14 (8.0)
1 (4.9) 44 (4.1) 14 (4.0) 4 (2.3)
9 (2.3) 21 (1.9) 7 (2.0) 4 (2.3)
9 (92.3) 1023 (94.5) 336 (95.7) 173 (98.3)
2 (7.4) 57 (5.3) 14 (4.0) 3 (1.7)
4 (0.3) 2 (0.2) 1 (0.3) 0 (0.0)
and were signiﬁcant (Po0.05) for all variables except lifetime number of male anal
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Clinical examinations were conducted at each visit. Using
prewetted Dacron swabs, genital specimens were collected from
the coronal sulcus/glans penis, penile shaft, and scrotum [13] and
combined into one sample per participant before being stored
at 80 °C. At a central laboratory, DNA was extracted from the
samples (QIAamp DNA Blood Mini Kit, Qiagen), followed by PCR
and HPV genotyping. Samples that tested positive for β-globin or
at least one HPV genotype were considered adequate and were
included in the analysis (overall β-globin positivity 98%). The
Linear Array assay (Roche Diagnostics) was utilized for detection of
37 HPV genotypes classiﬁed as high-risk (oncogenic; HPV 16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) or low-risk (non-
oncogenic; HPV 6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 66, 67, 69,
70, 71, 72, 73, 81, 82, 82 subtype IS39, 83, 84, and 89 [formerly
CP6108]) [14].
2.3. Statistical analysis
Genotype-speciﬁc HPV infections were reported individually
and by groups (“any”, “high-risk”, “low-risk”, and “9-valent vac-
cine”). The “any” group included those positive for Z1 of the 37
HPV genotypes. HPV infections with single or multiple high-risk
types were classiﬁed as high-risk. Similarly, HPV infections with at
least one low-risk HPV type were classiﬁed as low-risk, and HPV
infections with at least one of the genotypes targeted by the newly
licensed 9-valent HPV vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, or
58) were included in the “9-valent vaccine” group.
For individual and grouped HPV incidence analyses, only the
ﬁrst acquired infection was considered for a given HPV type or
group. Incidence analyses included only men who tested negative
for a given individual HPV type or grouped HPV infection category
at baseline. Cumulative risk of HPV incidence was estimated using
the Kaplan–Meier (KM) method. Associations between age and
HPV incidence were assessed using Cox proportional hazards (PH)
regression. Baseline factors included in modeling are shown in
Table 1. For each individual or grouped HPV incidence, backward
selection methods were used to facilitate variable selection for the
multivariable models. Design variables (age and country) and
those variables found to be statistically signiﬁcant by backward
selection methods (race, circumcision status, total and recent
numbers of sexual partners, smoking status, education, and mar-
ital status) were included in the ﬁnal multivariable models.
HPV clearance was deﬁned as two consecutive negative test
results following a positive test, excluding infections detected for the
ﬁrst time at a participant's ﬁnal visit and prevalent infections. For
grouped HPV clearance analyses, we adjusted for within-subject
correlation, as men may have been infected with multiple HPV
types within a deﬁned group (e.g., positive for both HPV 16 and HPV
18, which are both considered high-risk). The median time to HPV
clearance (median duration) among men with an incidently detected
infection was estimated using the KM method for individual HPV
infections, with the clustered KM method used for grouped HPV
infections [15]. To model the associations between age and HPV
clearance, we employed Cox PH regression with and without the
robust covariance matrix estimator [16] for grouped and individual
HPV clearance, respectively. The same variable selection procedure
described above was applied in building multivariable clearance
models, using data collected at the baseline visit. Although we did not
include prevalent HPV infections in clearance estimates, we included
baseline HPV status as a covariate in our clearance models, as it has
been shown to signiﬁcantly impact HPV clearance estimates for
subsequent incidently detected HPV infections [17].
Participant characteristics were compared across age groups
using the Monte Carlo estimation of the exact Pearson chi-squaretest. Age, our primary factor of interest, was primarily treated as a
categorical variable with ﬁve age groups: 18–24, 25–34, 35–44,
45–54, and 55–70 years. KM curves of HPV incidence and clear-
ance for these ﬁve age groups were also generated.
To thoroughly investigate the association between age and HPV
endpoints, we used Cox modeling and the same set of covariates,
treating age in the following ways: (1) as a categorical variable with
three pre-speciﬁed age groups, (2) as a categorical variable with ﬁve
pre-speciﬁed age groups, and (3) as a continuous variable.
All analyses were performed using SAS version 9.3 (SAS Insti-
tute, Cary, NC). All statistical tests were two-sided and considered
signiﬁcant at α¼0.05.3. Results
A total of 4085 men were followed for a median of 48.6 (range:
0.3–94.0) months. Demographic and behavioral characteristics are
reported in Table 1. Overall, the majority of participants were ages
18–34 (60.6%), white (44.5%), non-smokers (76.0%), and uncir-
cumcised (62.9%). Socio-demographic characteristics and sexual
behaviors differed signiﬁcantly by age group for all variables
examined except lifetime number of male anal sex partners. For
example, lifetime number of female sex partners reported was
highest among the oldest age groups and number of recent female
sex partners was lowest among the oldest age groups. However,
8% of men in the oldest age group (55–70 years) report having
three or more female sexual partners within the last six months,
indicating that older men within this study remain sexually active.
HPV infection incidence rates per 1000 person-months (Table 2)
for “any HPV” remained stable across age groups (Table 2), while
incidence rates for high-risk infections were signiﬁcantly lower
among men ages 35–44 and ages 55–70, compared to the youngest
age group (ages 18–24). Incidence of grouped low-risk HPV infections
peaked at ages 25–34 (24.5/1000 person months) and declined by
27% among those ages 55–70 years, where the incidence rate was
signiﬁcantly lower (17.9/1000 person months). HPV infection inci-
dence of the 9-valent HPV vaccine types was fairly constant across
the lifespan, with a 24% non-signiﬁcant decline from ages 18–24 to
55–70 years; however, a signiﬁcantly lower incidence was observed
among men ages 35–44 compared to those ages 18–24 years. Inci-
dence rates for individual HPV types followed different patterns
depending on genotype. HPV 16 incidence declined linearly with age,
with a 46% signiﬁcant drop in incidence comparing men in the
youngest and oldest age groups. Among individual low-risk HPV
genotypes, the highest HPV 6 incidence rates were found among men
in the youngest two age groups (18–34), after which incidence
decreased signiﬁcantly by 43% among men 55–70 years.
Fig. 1 presents the KM curves for HPV acquisition across all age
groups over the follow-up period. Overall, signiﬁcant differences
in HPV 6 and 16 acquisition were observed by age group. For both
HPV types, younger men (ages 18–34) had higher rates of infection
acquisition.
Signiﬁcant age-related decreases in HPV infection median dura-
tion (time to clearance) across the ﬁve age groups (Table 3; Fig. 2)
were observed for all grouped infections (any HPV, low-risk HPV,
high-risk HPV, and 9v HPV). Signiﬁcant declines in durationwere also
observed for individual high-risk HPV types 16 and 51 and individual
low-risk HPV types 40, 62, 73, and 82. Of these, all had the highest
median duration among the youngest age groups (18–24 and 25–34
years) with the exception of HPV 82, for which median duration was
higher in the oldest age group (55–70 years). Fig. 2 presents KM
curves for high risk, low risk, HPV 16 and HPV 6 infection HPV
duration by age group. While signiﬁcant differences were observed
for high and low risk HPV time to clearance by age group, the dif-
ferences appear minimal. In contrast, signiﬁcant differences in HPV
Table 2
Incidence rates of genital HPV infection among men in the HIM Study (N¼ 4032).
Ages 18–24 Ages 25–34 Ages 35–44 Ages 45–54 Ages 55–70
No. Infec-
tions
Incidence
Rate (95%
CI)a
No. Infec-
tions
Incidence
Rate (95%
CI)a
IRRb(95% CI)a No. Infec-
tions
Incidence
Rate (95%
CI)a
IRRb(95% CI)a No. Infec-
tions
Incidence
Rate (95%
CI)a
IRRb(95% CI)a No. Infec-
tions
Incidence
Rate (95%
CI)a
IRRb(95% CI)a
Any
HPV
412 30.7 (27.8–
33.8)
350 30.5 (27.4–
33.8)
0.99 (0.86–1.15) 324 29.5 (26.4–
32.9)
0.96 (0.83–1.11) 102 25.4 (20.7–
30.8)
0.83 (0.67–1.03) 50 23.9 (17.8–
31.5)
0.78 (0.58–1.04)
HR
HPV
421 19.6 (17.8–
21.6)
404 17.7 (16.0–
19.6)
0.90 (0.79–1.04) 377 16.2 (14.6–
17.9)
0.83 (0.72–0.95) 124 16.1 (13.4–
19.1)
0.82 (0.67–1.00) 51 13.9 (10.3–
18.2)
0.71 (0.53–0.95)
HPV
16
183 5.0 (4.3–5.8) 176 4.0 (3.5–4.7) 0.80 (0.65–0.98) 120 3.0 (2.5–3.6) 0.60 (0.48–0.76) 43 3.3 (2.4–4.4) 0.66 (0.47–0.92) 19 2.7 (1.6–4.3) 0.54 (0.34–0.87)
HPV
18
91 2.2 (1.8–2.7) 95 1.9 (1.6–2.4) 0.86 (0.65–1.15) 49 1.1 (0.8–1.4) 0.50 (0.35–0.71) 22 1.5 (1.0–2.3) 0.68 (0.43–1.09) 8 1.1 (0.5–2.2) 0.50 (0.24–1.03)
HPV
31
68 1.6 (1.2–2.0) 66 1.3 (1.0–1.7) 0.81 (0.58–1.14) 44 1.0 (0.7–1.3) 0.63 (0.43–0.91) 13 0.9 (0.5–1.5) 0.56 (0.31–1.02) 8 1.1 (0.5–2.1) 0.69 (0.33–1.43)
HPV
33
21 0.5 (0.3–0.7) 18 0.4 (0.2–0.6) 0.80 (0.43–1.50) 16 0.4 (0.2–0.6) 0.80 (0.42–1.53) 7 0.5 (0.2–1.0) 1.00 (0.43–2.35) 2 0.3 (0.0–0.9) 0.60 (0.14–2.56)
HPV
39
128 3.2 (2.7–3.8) 96 2.0 (1.6–2.5) 0.63 (0.48–0.81) 64 1.5 (1.2–1.9) 0.47 (0.35–0.63) 21 1.5 (0.9–2.2) 0.47 (0.30–0.74) 9 1.3 (0.6–2.4) 0.41 (0.21–0.80)
HPV
45
66 1.5 (1.2–1.9) 84 1.7 (1.4–2.1) 1.13 (0.82–1.56) 79 1.8 (1.4–2.3) 1.20 (0.87–1.66) 21 1.5 (0.9–2.2) 1.00 (0.61–1.63) 5 0.7 (0.2–1.6) 0.47 (0.19–1.16)
HPV
51
208 5.7 (4.9–6.5) 159 3.6 (3.0–4.1) 0.63 (0.51–0.78) 130 3.2 (2.7–3.8) 0.56 (0.45–0.70) 41 3.0 (2.2–4.1) 0.53 (0.38–0.74) 16 2.4 (1.3–3.8) 0.42 (0.25–0.70)
HPV
52
131 3.3 (2.7–3.9) 122 2.6 (2.1–3.1) 0.79 (0.62–1.01) 101 2.4 (2.0–2.9) 0.73 (0.56–0.94) 34 2.4 (1.7–3.4) 0.73 (0.50–1.06) 17 2.6 (1.5–4.1) 0.79 (0.48–1.31)
HPV
58
82 1.9 (1.5–2.4) 66 1.4 (1.0–1.7) 0.74 (0.53–1.02) 54 1.2 (0.9–1.6) 0.63 (0.45–0.89) 23 1.6 (1.0–2.4) 0.84 (0.53–1.34) 7 1.0 (0.4–2.0) 0.53 (0.24–1.14)
HPV
59
168 4.4 (3.8–5.1) 142 3.1 (2.6–3.7) 0.70 (0.56–0.88) 99 2.4 (1.9–2.9) 0.55 (0.43–0.70) 36 2.7 (1.9–3.7) 0.61 (0.43–0.88) 16 2.4 (1.3–3.8) 0.55 (0.33–0.91)
LR
HPV
443 24.2 (22.0–
26.5)
396 24.5 (22.1–
27.0)
1.01 (0.88–1.16) 324 21.4 (19.1–
23.8)
0.88 (0.77–1.02) 111 20.5 (16.9–
24.7)
0.85 (0.69–1.04) 54 17.9 (13.4–
23.3)
0.74 (0.56–0.98)
HPV 6 142 3.7 (3.1–4.4) 163 3.7 (3.2–4.3) 1.00 (0.80–1.25) 98 2.4 (1.9–2.9) 0.65 (0.50–0.84) 26 1.9 (1.3–2.8) 0.51 (0.34–0.78) 15 2.1 (1.2–3.5) 0.57 (0.33–0.97)
HPV
11
40 0.9 (0.7–1.3) 56 1.1 (0.8–1.5) 1.22 (0.81–1.83) 37 0.8 (0.6–1.1) 0.89 (0.57–1.39) 6 0.4 (0.1–0.9) 0.44 (0.19–1.05) 6 0.8 (0.3–1.8) 0.89 (0.38–2.10)
HPV
53
146 3.7 (3.1–4.3) 174 3.9 (3.4–4.5) 1.05 (0.85–1.31) 112 2.7 (2.3–3.3) 0.73 (0.57–0.93) 44 3.4 (2.4–4.5) 0.92 (0.66–1.29) 23 3.6 (2.3–5.4) 0.97 (0.63–1.51)
HPV
61
90 2.2 (1.7–2.7) 147 3.2 (2.7–3.8) 1.45 (1.12–1.89) 124 3.0 (2.5–3.6) 1.36 (1.04–1.79) 43 3.2 (2.3–4.2) 1.45 (1.01–2.09) 17 2.5 (1.4–4.0) 1.14 (0.68–1.91)
HPV
62
164 4.2 (3.6–4.9) 164 3.7 (3.2–4.4) 0.88 (0.71–1.09) 149 3.9 (3.3–4.6) 0.93 (0.74–1.16) 49 3.9 (2.9–5.1) 0.93 (0.67–1.28) 26 4.3 (2.8–6.3) 1.02 (0.68–1.55)
HPV
66
160 4.1 (3.5–4.8) 144 3.1 (2.6–3.7) 0.76 (0.60–0.95) 113 2.7 (2.2–3.3) 0.66 (0.52–0.84) 29 2.1 (1.4–3.1) 0.51 (0.34–0.76) 15 2.2 (1.2–3.5) 0.54 (0.32–0.91)
HPV
84
226 6.3 (5.5–7.2) 172 4.0 (3.4–4.6) 0.63 (0.52–0.77) 128 3.3 (2.7–3.9) 0.52 (0.42–0.65) 55 4.3 (3.2–5.6) 0.68 (0.51–0.92) 23 3.6 (2.3–5.4) 0.57 (0.37–0.88)
HPV
89c
223 5.9 (5.2–6.7) 173 3.9 (3.4–4.6) 0.66 (0.54–0.81) 140 3.5 (3.0–4.2) 0.59 (0.48–0.73) 49 3.7 (2.7–4.9) 0.63 (0.46–0.85) 18 2.6 (1.6–4.2) 0.44 (0.27–0.71)
HPV
9vd
359 14.1 (12.7–
15.7)
378 13.4 (12.0–
14.8)
0.95 (0.82–1.10) 310 11.2 (10.0–
12.5)
0.79 (0.68–0.92) 108 11.8 (9.7–
14.2)
0.84 (0.67–1.04) 53 10.7 (8.0–
14.0)
0.76 (0.57–1.01)
Note: HR: high-risk, LR: low risk, IRR: incidence rate ratio, CI: conﬁdence interval. Although 37 high- and low-risk HPV types are evaluated using the Roche Linear Array method, data are only shown for individual types included in
the 9-valent HPV vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58) and those that had incidence rates 43.0 in any age group.
a Incidence rate is estimated as the number of cases per 1000 person-months.
b IRRs were calculated using 18–24 years as the referent age group, with signiﬁcant values indicated in bold.
c Formerly HPV CP 6108.
d One or more of the 9-valent HPV vaccine types.
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Fig. 1. Kaplan–Meier analyses for incidence of grouped (A) high-risk and (B) low-risk HPV infections and of type-speciﬁc infections with (C) HPV 16 and (D) HPV 6, stratiﬁed
by ﬁve age groups (18–24, 25–34, 35–44, 45–54, 55–70 years). Signiﬁcant differences in incidence by age were observed for individual HPV types 6, 16, 18, 39, 51, 59, 61, 67,
71, and 84. Incidence did not vary signiﬁcantly by age within any of the grouped HPV infection categories or among infections with other individual HPV types.
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Table 3
Median duration of incident HPV infection among men in the HIM Study by age (N¼4085).
Median duration, months (95% CI) p value*
Ages 18–24 Ages 25–34 Ages 35–44 Ages 45–54 Ages 55–70
Any HPV 9.4 (8.3–11.3) 7.9 (7.5–8.5) 7.0 (6.8–7.4) 6.6 (6.4–7.1) 6.4 (6.2–7.4) o0.001
High-risk HPV 8.7 (7.6–10.4) 8.3 (7.4–10.1) 6.9 (6.5–7.4) 6.6 (6.3–7.4) 6.4 (6.2–8.1) 0.048
HPV 16 12.2 (9.8–14.7) 6.8 (6.3–8.0) 6.9 (6.2–8.1) 7.0 (6.0–12.5) 6.3 (5.8–11.5) 0.038
HPV 18 8.1 (6.5–11.9) 8.0 (6.2–11.9) 8.5 (6.2–11.6) 6.2 (5.9–7.4) 6.8 (5.7-NE) 0.865
HPV 31 6.9 (6.4–12.1) 10.5 (6.7–12.4) 6.7 (6.0–10.5) 6.4 (5.7-NE) 6.4 (5.7-NE) 0.839
HPV 33 6.2 (5.9–12.0) 6.0 (5.7–6.9) 7.3 (5.8–12.3) 6.6 (5.5-NE) 12.2 (NE-NE) 0.892
HPV 35 6.9 (6.2–12.0) 14.5 (7.1–23.1) 8.3 (6.2–17.8) 12.5 (6.4-NE) 24.7 (18.1-NE) 0.474
HPV 39 8.9 (7.1–12.0) 13.4 (7.2–22.8) 12.2 (7.2–15.2) 8.6 (6.0–18.2) 9.6 (6.0–18.2) 0.267
HPV 45 6.2 (6.1–6.7) 7.8 (6.2–12.6) 6.2 (6.0–6.7) 10.7 (6.8–16.1) 9.0 (6.0-NE) 0.070
HPV 51 12.1 (8.0–14.0) 11.7 (7.9–16.3) 7.8 (6.5–11.8) 6.4 (6.0–8.1) 6.4 (5.7–17.2) 0.032
HPV 52 8.8 (6.4–13.1) 7.3 (6.4–10.6) 6.5 (6.0–6.9) 6.7 (6.0–17.1) 9.2 (5.9–13.2) 0.337
HPV 56 6.9 (6.3–8.5) 11.6 (6.4–13.7) 6.2 (5.9–9.8) 6.0 (5.6–6.6) 6.2 (5.7–12.4) 0.092
HPV 58 11.5 (7.3–12.8) 12.5 (11.2–17.4) 7.7 (6.0–12.6) 6.2 (5.9–26.6) 5.9 (5.1-NE) 0.173
HPV 59 11.3 (7.0–12.5) 6.6 (6.1–8.2) 6.7 (6.0–9.3) 6.5 (5.8–12.5) 6.2 (5.7–7.3) 0.322
HPV 68 7.1 (6.3–7.7) 6.7 (6.1–8.2) 6.8 (6.0–8.5) 6.0 (5.7–6.4) 8.4 (5.7-NE) 0.406
Low-risk HPV 10.4 (8.7–11.9) 7.9 (7.3–8.3) 7.1 (6.8–7.7) 6.6 (6.4–7.4) 6.4 (6.2–8.0) o0.001
HPV 6 11.0 (7.8–12.2) 7.1 (6.2–8.3) 6.2 (6.0–7.8) 6.3 (6.0–7.1) 6.3 (5.7–8.4) 0.070
HPV 11 7.8 (6.2–18.0) 11.5 (6.4–12.9) 6.2 (6.0–6.9) 6.9 (5.6-NE) 7.2 (5.5-NE) 0.236
HPV26 6.7 (6.0–9.9) 6.3 (5.6–11.7) 6.9 (5.8–11.7) 5.7 (5.5-NE) NE 0.058
HPV 40 12.4 (7.2–15.6) 7.6 (6.2–12) 7.8 (6.2–17.3) 5.9 (5.5–6.4) 6.4 (5.7-NE) 0.021
HPV 42 11.7 (7.4–14.6) 8.7 (6.4–12.3) 6.8 (6.0–12.4) 12.0 (5.3-NE) 6.2 (5.1-NE) 0.166
HPV 53 9.9 (6.5–12.4) 7.3 (6.6–8.8) 7.4 (6.1–10.7) 7.5 (6.1–18.2) 15.7 (6.8–18.1) 0.901
HPV 54 12.2 (8.5–17.6) 8.0 (6.6–12) 8.2 (6.4–13.6) 6.4 (6.0–31.5) 6.4 (5.5–10.3) 0.071
HPV 55 12.0 (7.0–18.7) 6.7 (6.1–11.5) 7.3 (6.5–11.7) 6.8 (6.0–24.4) 6.1 (5.7-NE) 0.666
HPV 61 13.4 (7.6–17.6) 7.1 (6.6–11.2) 8.0 (6.8–12.2) 6.3 (5.9–12.0) 7.9 (5.5–12.2) 0.145
HPV 62 12.3 (8.3–18.6) 7.8 (6.7–12.4) 6.9 (6.4–8.0) 8.8 (6.4–12.5) 6.4 (6.0–11.0) 0.046
HPV 64 6.2 (5.6-NE) 5.9 (5.3–6.2) 6.1 (5.5-NE) 6.2 (5.5-NE) 9.0 (6.0-NE) 0.967
HPV 66 12.0 (7.6–16.2) 11.2 (6.7–12.6) 8.1 (6.6–11.9) 7.1 (6.0–11.9) 6.0 (5.6–17.4) 0.248
HPV 67 6.3 (6.0–7.1) 6.3 (6.0–6.9) 7.6 (6.0–13.4) 6.3 (6.0-NE) 5.8 (5.5-NE) 0.111
HPV 69 7.8 (5.5-NE) 7.9 (5.6-NE) 5.9 (5.7–13.4) 5.5 (5.3-NE) 5.8 (NE-NE) 0.097
HPV 70 7.0 (6.3–11.3) 6.8 (6.3–11.1) 6.7 (6.0–11.3) 6.8 (6.0-NE) 6.7 (5.3–42.2) 0.903
HPV 71 7.5 (6.0–17.7) 11.5 (6.8–23.1) 12.2 (6.2–23.0) 6.3 (5.8–18.5) 16.1 (6.7-NE) 0.974
HPV 72 6.2 (5.9–8.1) 6.4 (6.1–7.4) 6.4 (6.0–12.0) 6.0 (5.9–17.5) 6.0 (5.7–17.8) 0.918
HPV 73 9.2 (6.8–13.6) 10.1 (6.4–12.9) 6.7 (6.0–16.9) 6.1 (6.0–6.4) 6.0 (5.7-NE) 0.031
HPV 81 6.4 (6.2–9.4) 8.0 (6.9–12) 8.4 (6.6–12.0) 6.8 (5.9–7.7) 10.8 (5.7-NE) 0.659
HPV 82 6.5 (6.1–8.9) 6.9 (5.9–15.2) 6.5 (5.9–7.7) 5.7 (5.5-NE) 12.4 (11.7-NE) 0.018
HPV 82sa 9.9 (6.0–17.9) 13.2 (6.0–23.7) 12.2 (6.7–15.6) 6.2 (6.0-NE) 18.2 (5.7-NE) 0.438
HPV 83 6.7 (6.2–9.9) 11.3 (7.2–14.5) 6.9 (6.2–11.7) 24.6 (11.5-NE) 6.2 (5.7-NE) 0.007
HPV 84 12.5 (9.9–19.8) 12 (7.6–17.7) 6.8 (6.2–8.3) 6.6 (6.1–12.8) 6.6 (6.0–18.3) 0.078
HPV 89b 12.3 (7.8–16.2) 7.9 (6.6–11.4) 7.1 (6.4–11.8) 7.6 (6.0–16.8) 6.0 (5.7–25.7) 0.148
HPV 9vc 9.3 (7.8–11.3) 7.8 (7.1–8.8) 6.5 (6.2–6.9) 6.7 (6.3–7.7) 6.4 (6.2–7.6) 0.014
Note: 95% CI¼95% Conﬁdence interval. NE¼Non-estimable.
a HPV 82 subtype IS39.
b Formerly HPV CP6108.
c One or more of the 9-valent HPV vaccine types (6, 11, 16, 18, 31, 33, 45, 52, 58).
* P values for grouped infections and type-speciﬁc infections were derived from Kaplan–Meier curves of HPV infection clearance (Fig. 2) comparing the ﬁve age groups
across the entire follow-up period. Values in bold denote statistical signiﬁcance.
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observed, with time to clearance longer among the younger age
groups.
3.1. HPV infection incidence: associations with age
We examined the associations between age and genital HPV
incidence using multiple approaches, considering age as a cate-
gorical variable (three and ﬁve pre-speciﬁed age groups) and as a
continuous variable (Table 4). All three approaches were con-
sistent in demonstrating signiﬁcantly lower HPV incidence with
age for grouped high-risk infections, HPV 16, and HPV 6 infections.
3.2. HPV infection clearance: associations with age
Overall, when treating age as a categorical variable, likelihood
of grouped high-risk HPV infection clearance was signiﬁcantly
greater among men ages 45 and older, although the magnitude of
the difference was low (17–18% increased likelihood of clearancecompared to younger men). Likelihood of clearing HPV 6 and 16
infections remained constant across the lifespan when age was
treated as a continuous variable or categorized into tertiles. HPV
6 and 16 clearance was signiﬁcantly higher only when age was
categorized into quintiles, with men in the oldest age group (55–
70 years) having a 92% and 65% higher likelihood of infection
clearance, respectively (Table 5).4. Discussion
Despite differences in ages at which men develop genital warts
and penile cancer, rates of detection of incident genital HPV
infection in this multinational cohort of men remained relatively
stable across age groups, with different patterns observed across
various HPV types. Risk of incident infection detection was lower
for high-risk HPV, low-risk HPV, and individual HPV types 6 and
16 among older men. Likelihood of clearing HPV 16 and 6 infec-
tions remained fairly constant across the lifespan and was only
Fig. 2. Kaplan–Meier analyses for incidence of grouped (A) high-risk and (B) low-risk HPV infections and of type-speciﬁc infections with (C) HPV 16 and (D) HPV 6, stratiﬁed
by ﬁve age groups (18–24, 25–34, 35–44, 45–54, 55–70 years). Signiﬁcant differences in age for clearance were observed for grouped “any HPV,” “low-risk HPV,” and “HPV
9v” infections, as well as for type-speciﬁc infections with HPV 6, 51, 54, and 66. Clearance did not vary signiﬁcantly by age for any of the other grouped or type-speciﬁc
infections analyzed.
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Table 4
Effect of age on HPV infection incidence among men.
High-risk HPV Low-risk HPV HPV 16 HPV 6
HR (95% CI) AHR (95% CI) HR (95% CI) AHR (95% CI) HR (95% CI) AHR (95% CI) HR (95% CI) AHR (95% CI)
Three age groups
18–30 1.00 1.00 1.00 1.00
31–44 0.91 (0.81–1.01) 0.87 (0.76–0.99) 0.96 (0.85–1.08) 0.97 (0.84–1.13) 0.69 (0.57–0.83) 0.64 (0.53–0.78) 0.77 (0.63–0.94) 0.75 (0.61–0.92)
45–70 0.84 (0.71–1.00) 0.82 (0.67–0.99) 0.86 (0.72–1.02) 0.82 (0.66–1.01) 0.67 (0.51–0.88) 0.61 (0.46–0.80) 0.56 (0.40–0.78) 0.60 (0.43–0.84)
Five age groups
18–24 1.00 1.00 1.00 1.00
25–34 0.92 (0.81–1.06) 0.85 (0.72–1.00) 1.05 (0.91–1.2) 0.91 (0.77–1.08) 0.82 (0.67–1.01) 0.78 (0.62–0.98) 1.03 (0.82–1.29) 0.99 (0.78–1.26)
35–44 0.86 (0.74–0.98) 0.76 (0.64–0.92) 0.92 (0.80–1.06) 0.84 (0.70–1.02) 0.61 (0.49–0.77) 0.56 (0.43–0.72) 0.67 (0.52–0.87) 0.66 (0.50–0.87)
45–54 0.85 (0.70–1.04) 0.76 (0.59–0.96) 0.90 (0.73–1.11) 0.76 (0.58–0.98) 0.67 (0.48–0.94) 0.61 (0.43–0.86) 0.55 (0.36–0.84) 0.58 (0.38–0.89)
55–70 0.74 (0.55–0.99) 0.68 (0.49–0.94) 0.80 (0.60–1.06) 0.70 (0.51–0.98) 0.57 (0.36–0.92) 0.49 (0.30–0.79) 0.60 (0.35–1.02) 0.65 (0.38–1.12)
Continuous
18–70 0.94 (0.90–0.99) 0.92 (0.86–0.98) 0.96 (0.91–1.00) 0.88 (0.83–0.93) 0.84 (0.78–0.91) 0.81 (0.74–0.88) 0.83 (0.76–0.91) 0.84 (0.76–0.92)
Note: HR¼hazard ratio; AHR¼adjusted hazard ratio; CI¼conﬁdence interval. Associations between age and HPV incidence were assessed using Cox proportional hazards
regression. Design variables (country and age) were forced into multivariable models. Race, circumcision status, total and recent numbers of female and male sexual partners,
smoking status, education, and marital status were all included in multivariable modeling. Baseline measures were used for all variables. Bold values denote statistical
signiﬁcance in multivariable models.
Table 5
Effect of age on HPV infection clearance among men.
High-risk HPV Low-risk HPV HPV 16 HPV 6
HR (95% CI) AHR (95% CI) HR (95% CI) AHR (95% CI) HR (95% CI) AHR (95% CI) HR (95% CI) AHR (95% CI)
Three age groups
18–30 1.00 1.00 1.00 1.00
31–44 0.98 (0.91–1.05) 1.03 (0.95–1.11) 0.96 (0.91–1.02) 1.05 (0.98–1.12) 0.98 (0.82–1.16) 0.97 (0.81–1.16) 0.96 (0.79–1.16) 0.99 (0.81–1.20)
45–70 1.13 (1.00–1.26) 1.17 (1.04–1.32) 0.98 (0.89–1.08) 1.07 (0.96–1.19) 1.37 (1.06–1.77) 1.35 (1.04–1.76) 1.00 (0.71–1.41) 1.06 (0.75–1.50)
Five age groups
18–24 1.00 1.00 1.00 1.00
25–34 0.92 (0.85–1.00) 1.00 (0.92–1.09) 0.96 (0.89–1.03) 1.09 (1.00–1.18) 1.04 (0.86–1.25) 1.02 (0.84–1.23) 1.07 (0.88–1.3) 1.09 (0.89–1.35)
35–44 0.96 (0.88–1.05) 1.04 (0.95–1.15) 0.97 (0.90–1.04) 1.13 (1.03–1.23) 1.02 (0.82–1.26) 1.01 (0.81–1.25) 0.86 (0.68–1.09) 0.91 (0.71–1.16)
45–54 1.09 (0.95–1.26) 1.18 (1.02–1.37) 0.96 (0.86–1.07) 1.11 (0.98–1.26) 1.33 (0.98–1.81) 1.30 (0.95–1.78) 0.84 (0.55–1.27) 0.91 (0.59–1.40)
55–70 1.08 (0.89–1.30) 1.15 (0.95–1.39) 0.99 (0.85–1.16) 1.18 (1.00–1.40) 1.65 (1.05–2.60) 1.65 (1.06–2.56) 1.87 (1.42–2.48) 1.92 (1.34–2.74)
Continuous
18–70 1.02 (0.99–1.05) 1.05 (1.01–1.08) 0.99 (0.96–1.02) 1.04 (1.00–1.07) 1.07 (0.99–1.16) 1.07 (0.99–1.15) 1.00 (0.91–1.09) 1.02 (0.93–1.12)
Note: HR¼hazard ratio; AHR¼adjusted hazard ratio; CI¼conﬁdence interval. Associations between age and HPV incidence were assessed using Cox proportional hazards
regression. Design variables (country, age, and HPV positivity at enrollment) were forced into multivariable models. Race, circumcision status, total and recent numbers of
female and male sexual partners, smoking status, education, and marital status were all included in multivariable modeling. Baseline measures were used for all variables.
Bold values denote statistical signiﬁcance in multivariable models.
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remains unclear whether risk of progression to malignant and
benign lesions differs by age at which the infection was acquired.
Although we observed lower rates of incident infections at older
ages, there was continued detection of apparently new infections,
and duration of these detected infections was consistent across
most age groups. Altogether, it appears that men remain at risk for
prevalent genital HPV infection across the lifespan. To our
knowledge, this is the ﬁrst study to provide a comprehensive view
of incident HPV detection and duration by HPV genotype and age
over a relatively long follow-up period among men.
Previous studies have shown a bimodal age pattern of HPV
infection prevalence and incidence in women, with peaks near age
20 and between ages 45–50 in Latin American and other popula-
tions [9–11,18,19]. However, studies from other geographical
regions have not observed these trends [20,21]. The observed
differences between study populations may be explained by the
variation in HPV natural history by country or by differences in
sexual and other behavioral factors between populations. The
increase in HPV incidence at older ages in Latin American women
has been postulated to result from decreased immune response
over time, enabling latent infections to reactivate or new infec-
tions to persist for longer periods [22]. Results presented heresuggest an additional hypothesis in which women in the oldest
age group might acquire a new infection from their male partner,
as incident infection detection, although lower in older men, was
high among men of all ages in the U.S. and Latin America. While
number of recent partners declined with age, men in this study
remained sexually active across all age groups, potentially leading
to the introduction of new infections throughout the lifespan.
Furthermore, recent reports have demonstrated low rates of ser-
oconversion following natural HPV infection in men [23–25],
perhaps explaining in part the apparently continued risk of inci-
dent HPV detection in men across the lifespan.
Duration of HPV infections signiﬁcantly declined with age for
all grouped infections, as well as for a number of type-speciﬁc
infections, including HPV 16. Given the six-month sampling
intervals for HIM Study participants, duration estimates represent
maximum infection duration. However, these ﬁndings are con-
sistent with studies among women that demonstrate shorter
duration of newly acquired infections with age [26]. When pre-
valent HPV infections were considered, duration was highest
among older women, similar to what we have previously
demonstrated among men [13].
Although genital HPV 16 and other high-risk HPV infection
incidence declines with age, older men continue to acquire new
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infections continue to persist. These data correspond to the older
median ages of penile cancer diagnoses (Z60 years) and
emphasize the need for prevention interventions to have con-
tinued efﬁcacy in later years, especially given the low HPV ser-
oconversion rates among men. As the HPV vaccine has been
demonstrated to prevent genital warts and anal cancer in men
[27], it is of interest for future studies to determine whether
similar efﬁcacy occurs against other cancers in men, such as penile
cancer, and for sufﬁcient longevity (following adolescent vacci-
nation) to cover the entire period of HPV susceptibility.
Notable strengths of this study include the size and multi-
national nature of this male cohort, the long duration of follow-up,
and the use of multiple modeling strategies to assess associations
with age and HPV infection. Our methodologies were similar to
those employed in studies of female cohorts, providing the
opportunity to compare differences in trends between genders.
Additionally, the use of a computer-assisted self-interview (CASI)
at each visit was likely to reduce bias associated with answering
highly sensitive questions, such as those related to sexual beha-
vior. Although the HIM Study is not a population-based study, the
demographics of the men included at each of the three interna-
tional clinical sites are similar to the underlying population of men
ages 18–70 years in their respective communities [13] and, on
average, they have a similar sexual history and behavior to a
nationally representative group of men in the U.S. [13,28]. As such,
the incident HPV detection rates observed in this study likely
represent those one would observe in the population at large.
However, potential limitations that should be considered include a
possible lack of external validity due to the methods of recruit-
ment and extended length of follow-up, which may result in a
study cohort that is not reﬂective of the general population of the
participating countries. This work also utilized only baseline data
for demographic and behavioral factors, potentially limiting the
interpreted effect of time-varying covariates, such as sexual
behavior. However, baseline sexual behaviors, such as the number
of sexual partners in the past 3–6 months, reﬂected patterns that
continued through successive six-month follow-up visits (data not
shown). Additionally, estimates of HPV incidence and duration
were based on visits that occurred approximately every six
months and therefore do not reﬂect changes in infection status
that occurred during the intervening months. Furthermore,
despite the use of highly sensitive HPV DNA detection methods at
each study visit, infections deemed as “incident” may actually
represent reactivation of past infections, infections that were
prevalent at baseline but below the limits of detection, or presence
of virus on the skin surface that does not represent true infection.
Current laboratory methods do not distinguish reactivated latent
infections from those that are newly acquired.
In summary, the data presented here show that the age pat-
terning of incident genital HPV detection and duration in men
remains relatively constant across the lifespan. Given the higher
incidence of genital warts in young men and of penile cancers in
older men, it is therefore likely that other factors inﬂuence the
association between age and HPV-related diseases. Additionally,
while most HPV-related diseases in men are caused by HPV 16
(cancer) and 6 (genital warts), transmission of other high-risk HPV
types from men to women elevates risk of pre-cancer and cancer
in female partners. As such, the consistently high detection of
incident infections and duration of high-risk HPV types in men
across the lifespan support the need for effective interventions to
prevent infection and disease in both genders.Conﬂicts of interest
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